• हिन्दी
  • ગુજરાતી
  • বাংলা
  • తెలుగు
  • मराठी
  • ಕನ್ನಡ
  • money9
  • Insurance
  • Saving
  • Mutual Funds
  • Mirae Asset MF
  • Breaking Briefs
downloadDownload The App
Close
  • Home
  • Videos
  • Podcast
  • Banking
  • Bulletin
  • Gold
  • Healthcare
  • Real Estate
  • Tax
  • Travel
  • Survey 2023
  • Survey Report
  • Breaking Briefs
  • Insurance
  • Savings
  • Loan
  • Crypto
  • Investment
  • Mutual Funds
  • Real Estate
  • Tax
  • Exclusive
  • Home / Exclusive

Documents for Covaxin emergency use listing submitted to WHO; expect approval at earliest: Bharat Biotech

According to WHO, EUL is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies.

  • Press Trust of India
  • Last Updated : July 13, 2021, 13:13 IST
  • Follow
Bharat Biotech has submitted all documents required for emergency use listing (EUL) of Covaxin to WHO as of 9th July.
  • Follow

Bharat Biotech has said it has submitted all documents required for the emergency use listing (EUL) of its Covid-19 vaccine Covaxin to the world health organization (WHO) and expects a nod at the earliest.

Last week, WHO chief scientist Soumya Swaminathan had said that the global health body is likely to take a decision on Bharat Biotech’s Covid-19 vaccine Covaxin in the emergency use listing within four to six weeks.

“All documents required for emergency use listing (EUL) of Covaxin have been submitted to WHO as of 9th July. The review process has now commenced with the expectation that we will receive EUL from WHO at the earliest,” Bharat Biotech International Ltd CMD Krishna Ella said in a tweet posted by the company.

According to WHO guidelines, EUL is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies.

“We currently have six vaccines approved with EUL and have recommendations from our strategic advisory group of experts (SAGE). We continue to look at Covaxin. Bharat Biotech has now started uploading their data on our portal and that is the next vaccine that will be reviewed by our experts committee,” Swaminathan had said

Published: July 13, 2021, 13:13 IST

Download Money9 App for the latest updates on Personal Finance.

  • Bharat Biotech
  • Covaxin
  • Covid-19

Related

  • Indigo की 200 से ज्यादा फ्लाइट रद्द, हजारों पैसेंजर फंसे
  • भारत-रूस समिट में बड़े फैसलों की तैयारी, इकोनॉमिक पार्टनरशिप पर बड़ा फोकस
  • भारत और यूरोपीय संघ के बीच पैसे भेजना होगा आसान,RBI ने शुरू की UPI TIPS; जानें कैसे करेगा काम
  • श्रम संहिता लागू होने से निर्यातकों को मिलेगा प्रोत्साहन: अधिकारी
  • मारुति सुजुकी ने प्रौद्योगिकी स्टार्टअप में करीब आठ प्रतिशत हिस्सेदारी हासिल की
  • टोयोटा ने डैशबोर्ड के हिस्से को बदलने के लिए 11.5 हजार अर्बन क्रूजर हाइडर वापस मंगाईं

Latest

  • 1. Know the correct way to get KYC done!
  • 2. Why health insurance claim gets rejected?
  • 3. Power to Respond!
  • 4. What is Asset Under Management?
  • 5. No Worries on Medical Expenses!
  • Trending Stories

  • DGCA प्रमुख ने सुचारू उड़ान संचालन सुनिश्चित करने के लिए पायलटों से मांगा सहयोग
  • रेपो दर में कटौती से घर के लिए कर्ज होगा सस्ता, मांग बढ़ेगी: रियल एस्टेट
  • मीशो के 5,421 करोड़ रुपये के आईपीओ को दूसरे दिन मिला 7.97 गुना अभिदान
  • इंडिगो को अगले साल 10 फरवरी तक उड़ान संचालन पूरी तरह बहाल होने की उम्मीद
  • Indigo की 200 से ज्यादा फ्लाइट रद्द, हजारों पैसेंजर फंसे
  • TV9 Sites

  • TV9 Hindi
  • TV9Telugu.com
  • TV9 Marathi
  • TV9 Gujarati
  • TV9 Kannada
  • TV9 Bangla
  • TV9 English
  • News9 Live
  • Trends9
  • Tv9tamilnews
  • Assamtv9
  • Malayalamtv9
  • Money9 Sites

  • Money9 Hindi
  • Money9 English
  • Money9 Marathi
  • Money9 Telugu
  • Money9 Gujarati
  • Money9 Kannada
  • Money9 Bangla
  • Money9live
  • Topics

  • Insurance
  • Savings
  • Loan
  • Stocks
  • Mutual Funds
  • Real Estate
  • Tax
  • Crypto
  • Exclusive
  • Follow us

  • FaceBook
  • Twitter
  • Youtube
  • Instagram
  • Linkedin
  • Download App

  • play_store
  • App_store
  • Contact Us
  • About Us
  • Advertise With Us
  • Privacy & Cookies Notice
  • Complaint Redressal
  • Copyright © 2025 Money9. All rights reserved.
  • share
  • Facebook
  • Twitter
  • Whatsapp
  • LinkedIn
  • Telegram
close